The pace of the transition from scientific discovery to the marketplace in any specific medical field often affects the excitement that one sees in that industry from a clinical and commercial perspective. Technology advances in the device world – due partially to a less onerous regulatory environment – tend to reach the exhibit floor more rapidly than biopharma clinical outcomes.